FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Klein Lawrence Otto						2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  V Officer (give title Other (specify					vner		
(Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET						3. Date of Earliest Transaction (Month/Day/Year) 01/15/2021								X below) CBO & COO							
- TO THE HIT OTREET							4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139														X Form filed by One Reporting Person							
(City) (State) (Zip)				-									Form filed by More than One Reporting Person								
(City)	(5		(Zip)	lon Dori	vativ	0 50	if	ios Ac	· auiro	4 D	ienoeod o	of or Bo	nofici	ally	Owned						
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/N				tion	2A. Exe	Deem cution	ed n Date,	3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amou		nt of es ally	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial			
						(MO	ntn/Da	ay/Year)	8) Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3	d tion(s)	(I) (IN		Ownership (Instr. 4)		
Common Shares 01				01/15/2	2021				M		8,666	A	\$12.	\$12.57		,666		D			
Common Shares 01/15				01/15/2	2021						2,911	D	\$211.4	44(2)	25	5,755		D			
Common Shares 01/15/				2021				<b>S</b> <sup>(1)</sup>		2,555	D	\$212.	\$212.54 <sup>(3)</sup>		3,200		D				
Common Shares 0				01/15/2	01/15/2021				<b>S</b> <sup>(1)</sup>		1,200	D	\$213.71(4)		22,	2,000		D			
Common Shares 01/				01/15/2	2021				<b>S</b> <sup>(1)</sup>		1,400	D	\$214.	\$214.46 <sup>(5)</sup>		,600		D			
Common Shares				01/15/2	01/15/2021				<b>S</b> <sup>(1)</sup>		400	D	\$216.24(6)		20,	,200		D			
Common Shares 01				01/15/2	2021				<b>S</b> <sup>(1)</sup>		200	D	\$217.	\$217.45 <sup>(7)</sup>		,000		D			
Common Shares				01/15/2			M		16,344	A	\$14.43		36,	66,334		D					
Common Shares				01/15/2			<b>S</b> <sup>(1)</sup>		634	D	\$212.2(8)		35,	5,700		D					
Common Shares 0				01/15/2	01/15/2021						2,800	D	\$213.64 <sup>(9)</sup>		32,	32,900		D			
Common Shares 01				01/15/2	/15/2021				<b>S</b> <sup>(1)</sup>		700	D	\$214.6(10)		32	32,200		D			
Common Shares 01/1:				01/15/2	2021				<b>S</b> <sup>(1)</sup>		1,500	D	\$216.39(11)		30,700			D			
Common Shares 01/15				01/15/2	2021				<b>S</b> <sup>(1)</sup>		9,997	D	\$217.42(12)					D			
				01/15/2	2021				<b>S</b> <sup>(1)</sup>		701	1 1	\$218.54(13)					D			
Common Shares 01/15/20				2021	21			<b>S</b> <sup>(1)</sup>		2 D \$219.		\$219.9	99(14)	20,000		D					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Exercise (Month/Day/Year) if any ice of (Month/Day/Year)		med on Date,	4. Transa Code ( 8)	ction	5. Number of		6. Date Exerc Expiration D (Month/Day/		cisable and ate	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		int 8.	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
Stock					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amou or Numb of Share	er							
Option (Right to Buy)	\$12.57	01/15/2021						8,666	(1:	5)	07/14/2026	Common Shares	8,666		\$0.00	\$0.00		D			
Stock Option (Right to Buy)	\$14.43	01/15/2021			M			16,334	(16)		06/14/2027	Common Shares			\$0.00 14,666		5	D			

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$211.01 to \$212.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$212.01 to \$212.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$213.10 to \$214.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$214.125 to \$214.75, inclusive. The reporting person undertakes to provide

to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$216.15 to \$216.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$217.42 to \$217.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$212.01 to \$212.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$213.48 to \$214.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$214.60 to \$214.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$216.00 to \$216.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each securities.
- 12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$217.22 to \$217.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$218.25 to \$218.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$219.99 to \$219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 15. 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016.
- 16, 100% of the shares shall yest in 48 equal monthly installments on the fifteenth day of each month, with the first yesting event on July 15, 2017.

## Remarks:

/s/ Michael Esposito, attorney-

01/20/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.